Publishing: May 2021 | Report Code: LS10150 | Available Format: PDF
A biological marker, commonly known as a biomarker, measures and evaluates biological and pathogenic processes. It also measures pharmacological responses to a therapeutic intervention. Biomarkers are used in predictions, cause, diagnosis, progression, regression and outcome of various diseases. Biomarkers can be specific cell, molecules, genes, gene products, enzymes, hormones, complex organ functions, and general characteristic changes in biological structure.
Factors such as rising demand of personalized medicine, and companion diagnostics are some of the major growth drivers for the global biomarker market. Recent advancements in the discovery technologies such as genome sequencing are also contributing to the overall growth of the global biomarker market. Increasing personalized solution for cancer treatment, and prevention, rising interdisciplinary systems biology approach and development of OMICS technology is expected to drive the market during the forecast period.
High validation cost and high capital requirement for the discovery and development of biomarkers in drug developments are some of the major factors hindering the biomarkers market. Ethical and early diagnosis of the fatal diseases such as cancer and HIV are some major challenge for the biomarker market.
North America was the largest market of biomarkers in 2014. The market dominance of North America is attributed to the high concentration of pharmaceutical company and their research and development (R&D) center in this region, also the aging population and rising healthcare expenditure in North America is fueling the demand of biomarker in this region. Asia-Pacific market is estimated to be fasted growing market of biomarkers in coming years, attributed to the rising healthcare infrastructure and rising healthcare awareness among the consumers in developing countries. Country wise the U.S. and Canada are some of the major market of biomarkers in North America. Italy, Germany, Spain, the U.K., and France are some of the dominant biomarker market in Europe. China, India, and Japan are major biomarker market in Asia-Pacific.
Based on the discovery technologies the global biomarkers market can be broadly segmented as imaging technologies, OMICS technologies for biomarkers discovery, and bioinformatics. Further the imaging technologies can be further segmented as Positron Emission Tomography (PET), single-photon emission computed tomography (SPECT), ultrasound, magnetic resonance imaging (MRI), and computed tomography (CT). OMICS technologies for biomarkers discovery market can further be segmented as proteomics, genomics, transcriptomics, and metabolomics. The bioinformatics segment of biomarker market can further segmented as cluster analysis, statistical analysis, cell signal pathways, computer aided design, data mining, and protein interaction maps.
Based on the various services the global biomarker market can be segmented as clinical, and bioinformatics. Clinical segment can be further classified as sample preparation, assay development, and biomarkers validation & testing. Based on the various applications of biomarkers the global biomarkers market can be bifurcated as drug discovery & development, personalized medicine, and molecular diagnostics. The clinical trials segment can be further bifurcated as preclinical development phase I drug development, phase II drug development, phase III drug development, and phase IV drug development.
Based on the various diseases the global biomarkers market can be segmented as an oncology biomarkers market, cardiology biomarkers market, neurology biomarkers market, other indications biomarkers market, HIV, renal failure, arthritis, tuberculosis, and diabetes.
Some of the major players operating in the global biomarkers market include, Abbott Laboratories, Affymetrix Inc., Agilent Technologies Inc., Dickinson and Company, Becton, Celera Corporation., Epigenomics AG., Bruker Corporation, DiagnoCure Inc., GE Healthcare, Siemens AG, Thermo Fisher Scientific Inc., Bio-Rad Laboratories, Clarient Inc., hermo Fisher Scientific, Inc., Epistem Ltd., and Aushon BioSystem Inc.,
Our dedication to providing the most-accurate market information has earned us verification by Dun & Bradstreet (D&B). We strive for quality checking of the highest level to enable data-driven decision making for you
Our insights into the minutest levels of the markets, including the latest trends and competitive landscape, give you all the answers you need to take your business to new heights
With 24/7 research support, we ensure that the wheels of your business never stop turning. Don’t let time stand in your way. Get all your queries answered with a simple phone call or email, as and when required
We take a cautious approach to protecting your personal and confidential information. Trust is the strongest bond that connects us and our clients, and trust we build by complying with all international and domestic data protection and privacy laws